Metastatic melanoma and vemurafenib: novel approaches

被引：3
|
作者：
De Mello, Ramon Andrade [1 ,2 ]
机构：
[1] Portuguese Oncol Inst, Dept Med Oncol, Rua Dr Antonio Bernardino Almeida, P-4200072 Oporto, Portugal
[2] Univ Porto, Fac Med, Dept Med, Oporto, Portugal
来源：
RARE TUMORS | 2012年 / 4卷 / 02期
关键词：
malignant melanoma; dabrafenib; vemurafenib; BRAF V600 mutation; metastatic disease; skin cancer;
D O I：
10.4081/rt.2012.e31
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Metastatic melanoma (MM) presents a treatment challenge to oncologists worldwide. Dacarbazine is the first line chemotherapy treatment for MM, though the overall response rates are very poor. Recently, the v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600 mutation was found to play a main role in MM. This mutation is present in 40-60% of melanoma patients. Vemurafenib is a BRAF kinase inhibitor that showed impressive results in phase I-III trials and was thus recently approved for the treatment of MM. This paper will briefly focus on vemurafenib in the treatment of MM and highlight concerns
引用
收藏
页码：96 / 97
页数：2
相关论文
共 50 条
  • [41] Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients
    Daud, Adil
    Gill, Japinder
    Kamra, Sheily
    Chen, Lei
    Ahuja, Amit
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10 : 1 - 9
  • [42] Progression of KRAS mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma
    Grey, A.
    Cooper, A.
    McNeil, C.
    O'Toole, S.
    Thompson, J.
    Grimison, P.
    INTERNAL MEDICINE JOURNAL, 2014, 44 (06) : 597 - 600
  • [43] Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients
    Adil Daud
    Japinder Gill
    Sheily Kamra
    Lei Chen
    Amit Ahuja
    Journal of Hematology & Oncology, 10
  • [44] Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma
    Casey Quinn
    Qiufei Ma
    Amber Kudlac
    Stephen Palmer
    Beth Barber
    Zhongyun Zhao
    Advances in Therapy, 2016, 33 : 643 - 657
  • [45] Evolution of Melanocytic Nevi under Vemurafenib, Followed by Combination Therapy with Dabrafenib and Trametinib for Metastatic Melanoma
    Giurcaneanu, Calin
    Nitipir, Cornelia
    Popa, Liliana Gabriela
    Forsea, Ana Maria
    Popescu, Ioana
    Bumbacea, Roxana Silvia
    ACTA DERMATOVENEROLOGICA CROATICA, 2015, 23 (02) : 114 - 121
  • [46] Ipilimumab and Vemurafenib: Two Different Routes for Targeting Melanoma
    Burgeiro, Ana
    Mollinedo, Faustino
    Oliveira, Paulo J.
    CURRENT CANCER DRUG TARGETS, 2013, 13 (08) : 879 - 894
  • [47] Safety of vemurafenib in patients with BRAF V600 mutated metastatic melanoma: the Spanish experience
    Arance, A. M.
    Berrocal, A.
    Lopez-Martin, J. A.
    de la Cruz-Merino, L.
    Soriano, V.
    Martin Algarra, S.
    Alonso, L.
    Cerezuela, P.
    La Orden, B.
    Espinosa, E.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2016, 18 (11) : 1147 - 1157
  • [48] Response of metastatic glioma to vemurafenib
    Leaver, Katie Emily
    Zhang, Niushen
    Ziskin, Jennifer L.
    Vogel, Hannes
    Recht, Lawrence
    Thomas, Reena P.
    NEURO-ONCOLOGY PRACTICE, 2016, 3 (04) : 268 - 271
  • [49] Vemurafenib (PLX4032): An Orally Available Inhibitor of Mutated BRAF for the Treatment of Metastatic Melanoma
    Heakal, Yasser
    Kester, Mark
    Savage, Scott
    ANNALS OF PHARMACOTHERAPY, 2011, 45 (11) : 1399 - 1405
  • [50] Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma
    Quinn, Casey
    Ma, Qiufei
    Kudlac, Amber
    Palmer, Stephen
    Barber, Beth
    Zhao, Zhongyun
    ADVANCES IN THERAPY, 2016, 33 (04) : 643 - 657
12345